GlassScriptPhysician profile
Vibeth Atienza
NPI 1114220670
$2,293.23
in general payments reported to CMS, 2019-2025
29 companies · $620 in 2025
The $620 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $515 · 2022: $633 · 2023: $32.32 · 2024: $493 · 2025: $620.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $212.61 | 2022-2025 | Fasenra |
| Amgen INC. | $182.54 | 2022-2024 | Tepezza |
| Vertex Pharmaceuticals Incorporated | $153.92 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $137.76 | 2024 | Austedo Xr |
| Epizyme, INC. | $124.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $122.65 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $118.02 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.32 | 2025 | Jardiance |
| Pharmacyclics LLC, An Abbvie Company | $111.42 | 2021-2022 | |
| Seagen INC. | $105.74 | 2021 | |
| Beigene USA, INC. | $96.67 | 2021 | |
| Genzyme Corporation | $94.04 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $88.80 | 2024 | Nuplazid |
| Exact Sciences Corporation | $86.31 | 2025 | The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $82.91 | 2021-2024 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $82.16 | 2021-2023 | Pomalyst |
| Cvrx, INC. | $68.43 | 2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $41.31 | 2022 | |
| Astellas Pharma US INC | $40.57 | 2022 | |
| Janssen Biotech, INC. | $37.41 | 2022-2023 | Imbruvica, Darzalex |
| Pharmaessentia USA Corporation | $29.32 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.07 | 2022 | |
| Blueprint Medicines Corporation | $26.24 | 2022 | |
| Glaxosmithkline, LLC. | $24.60 | 2022 | |
| Alexion Pharmaceuticals, INC. | $20.81 | 2022 | |
| Emd Serono, INC. | $17.48 | 2021 | |
| Taiho Oncology, INC. | $16.79 | 2021 | |
| Acrotech Biopharma INC. | $14.52 | 2021 | |
| Organon LLC | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vibeth Atienza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.